Pasithea Therapeutics Corp. (KTTA) Balance Sheet
KTTA balance sheet, 2025
December 31, 2025 · U.S. dollars$60.2M assets = $5.0M liabilities + $55.2M equity
Both columns are drawn to the same scale: what KTTA owns equals what it owes plus shareholders’ equity. Hover a block for its value.
KTTA financial health
Descriptive bands, not a rating. Fiscal 2025.
KTTA balance sheet trends, 2020–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $247,9582020 | $60.2M2025 | +200.0%/yr | |
| Total liabilities | $6,6032020 | $5.0M2025 | +276.9%/yr | |
| Shareholders’ equity | $241,3552020 | $55.2M2025 | +196.4%/yr | |
| Cash & short-term investments | $243,6502020 | $55.2M2025 | +195.8%/yr | |
| Total debt | $504,3832022 | $81,6802023 | −83.8%/yr | |
| Net cash (debt) | $32.6M2022 | $16.2M2023 | −$16.3M | |
| Working capital | $241,3552020 | $51.5M2025 | +$51.2M | |
| Debt / equity | 0.012022 | 0.002023 | −0.01 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
KTTA assets
KTTA liabilities and equity
KTTA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
KTTA balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & short-term investments | $55.2M | $6.9M | $16.3M | $33.1M | $53.0M | $243,650 |
| Cash & equivalents | $55.2M | $6.9M | $16.3M | $33.1M | $53.0M | $243,650 |
| Short-term investments | — | $6.92B | — | — | — | — |
| Receivables | $0 | $0 | $40,500 | $302,132 | $0 | $0 |
| Inventory | $0 | $0 | −$40,500 | $1 | $0 | $0 |
| Other current assets | $1.3M | $445,586 | $361,102 | $686,696 | $333,751 | $4,308 |
| Total current assets | $56.5M | $7.4M | $16.7M | $34.1M | $53.3M | $247,958 |
| Property, plant & equipment (net) | $0 | $122,343 | $220,479 | $625,625 | $20,124 | $0 |
| Goodwill & intangible assets | $3.8M | $8.6M | $9.2M | $9.8M | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $643,382 | $0 | $0 |
| Total assets | $60.2M | $16.1M | $26.1M | $45.2M | $53.3M | $247,958 |
| Liabilities | ||||||
| Accounts payable | — | $1.1M | $2.6M | $1.5M | $447,280 | $6,603 |
| Short-term debt | — | — | $81,680 | $160,362 | — | — |
| Deferred revenue | — | — | −$2.6M | −$1.6M | — | — |
| Total current liabilities | $5.0M | $1.1M | $2.6M | $1.9M | $447,280 | $6,603 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | — | $0 | $81,680 | $926,887 | $0 | — |
| Other long-term liabilities | $46,871 | $162,172 | $84,366 | $804,207 | $1.5M | $0 |
| Total liabilities | $5.0M | $1.3M | $2.7M | $2.7M | $1.9M | $6,603 |
| Shareholders' equity | ||||||
| Common stock & paid-in capital | $2,309 | $139 | $104 | $130 | $17,684 | $14,938 |
| Retained earnings (deficit) | −$70.0M | −$49.6M | −$35.3M | −$19.4M | −$2.2M | −$40,984 |
| Accumulated other comprehensive income | $18,766 | −$7,171 | −$4,652 | −$661 | −$10,561 | $0 |
| Total shareholders' equity | $55.2M | $14.8M | $23.4M | $42.5M | $51.4M | $241,355 |
| Key figures | ||||||
| Total debt | — | — | $81,680 | $504,383 | — | — |
| Net cash (debt) | — | — | $16.2M | $32.6M | — | — |
| Working capital | $51.5M | $6.2M | $14.1M | $32.2M | $52.9M | $241,355 |
| Tangible book value | $51.4M | $6.2M | $14.2M | $32.7M | $51.4M | $241,355 |
| Book value per share | $7.85 | — | — | — | — | — |
| Shares outstanding | 7.0M | — | — | — | — | — |
| Current ratio | 11.35 | 6.58 | 6.34 | 18.15 | 119.17 | 37.55 |
| Quick ratio | 11.09 | 6.18 | 6.22 | 17.78 | 118.42 | 36.90 |
| Debt / equity | — | — | 0.00 | 0.01 | — | — |
| Equity / assets | 91.7% | 92.0% | 89.6% | 94.1% | 96.4% | 97.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $45.7M | $50.4M | $55.2M | $4.1M | $7.2M | $5.3M | $6.9M | $9.4M | $8.0M | $12.0M | $16.3M | $19.6M |
| Cash & equivalents | $45.7M | $50.4M | $55.2M | $4.1M | $7.2M | $5.3M | $6.9M | $9.4M | $8.0M | $12.0M | $16.3M | $19.6M |
| Short-term investments | — | — | — | — | — | — | — | $9.35B | — | — | — | — |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $40,500 | $40,500 | $95,000 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | −$40,500 | −$40,500 | $985,067 |
| Other current assets | $2.6M | $2.3M | $1.3M | $1.4M | $1.4M | $783,662 | $445,586 | $417,603 | $674,896 | $1.2M | $361,102 | $106,511 |
| Total current assets | $48.2M | $52.7M | $56.5M | $5.5M | $8.6M | $6.1M | $7.4M | $9.8M | $8.6M | $13.2M | $16.7M | $20.8M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $113,564 | $117,522 | $122,343 | $127,060 | $131,776 | $168,517 | $220,479 | $524,377 |
| Goodwill & intangible assets | $3.5M | $3.6M | $3.8M | $8.1M | $8.3M | $8.4M | $8.6M | $8.7M | $8.9M | $9.0M | $9.2M | $9.4M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $51.7M | $56.4M | $60.2M | $13.6M | $17.0M | $14.7M | $16.1M | $18.6M | $17.7M | $22.4M | $26.1M | $30.7M |
| Liabilities | ||||||||||||
| Accounts payable | $1.8M | $1.5M | — | $1.3M | $1.6M | $1.3M | $1.1M | $660,397 | $1.4M | $2.4M | $2.6M | $1.9M |
| Short-term debt | — | — | — | — | $155,455 | $268,969 | — | — | — | $32,989 | $81,680 | $174,471 |
| Deferred revenue | — | — | — | — | — | — | — | — | — | −$2.4M | −$2.6M | −$1.9M |
| Total current liabilities | $1.8M | $1.5M | $5.0M | $1.4M | $1.7M | $1.6M | $1.1M | $660,397 | $1.4M | $2.5M | $2.6M | $2.0M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | — | — | — | — | — | — | $0 | $0 | $0 | $32,989 | $81,680 | $385,288 |
| Other long-term liabilities | $32,341 | $52,966 | $46,871 | $46,871 | $93,741 | $85,305 | $162,172 | $163,578 | $93,272 | $57,650 | $84,366 | $239,876 |
| Total liabilities | $1.9M | $1.5M | $5.0M | $1.4M | $1.8M | $1.7M | $1.3M | $823,975 | $1.5M | $2.5M | $2.7M | $2.3M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $3,341 | $2,494 | $2,309 | $743 | $743 | $270 | $139 | $104 | $104 | $104 | $104 | $17,466 |
| Retained earnings (deficit) | −$78.2M | −$72.9M | −$70.0M | −$59.9M | −$56.9M | −$53.1M | −$49.6M | −$46.4M | −$43.0M | −$39.2M | −$35.3M | −$30.3M |
| Accumulated other comprehensive income | $9,570 | $46,898 | $18,766 | $18,301 | $5,631 | $0 | −$7,171 | −$35,317 | −$8,184 | −$5,272 | −$4,652 | −$7,717 |
| Total shareholders' equity | $49.8M | $54.8M | $55.2M | $12.2M | $15.2M | $13.0M | $14.8M | $17.8M | $16.2M | $19.9M | $23.4M | $28.4M |
| Key figures | ||||||||||||
| Total debt | — | — | — | — | $155,455 | $268,969 | — | — | — | $32,989 | $81,680 | $385,288 |
| Net cash (debt) | — | — | — | — | $7.1M | $5.1M | — | — | — | $12.0M | $16.2M | $19.2M |
| Working capital | $46.4M | $51.2M | $51.5M | $4.2M | $6.9M | $4.5M | $6.2M | $9.1M | $7.2M | $10.7M | $14.1M | $18.7M |
| Tangible book value | $46.4M | $51.2M | $51.4M | $4.1M | $6.9M | $4.6M | $6.2M | $9.1M | $7.3M | $10.8M | $14.2M | $19.0M |
| Book value per share | $7.09 | $7.80 | $7.85 | $1.64 | — | — | — | — | — | — | — | — |
| Shares outstanding | 7.0M | 7.0M | 7.0M | 7.4M | — | — | — | — | — | — | — | — |
| Current ratio | 26.25 | 35.40 | 11.35 | 4.02 | 4.97 | 3.84 | 6.58 | 14.81 | 6.20 | 5.35 | 6.34 | 10.16 |
| Quick ratio | 24.85 | 33.84 | 11.09 | 2.99 | 4.15 | 3.35 | 6.18 | 14.18 | 5.71 | 4.88 | 6.22 | 9.63 |
| Debt / equity | — | — | — | — | 0.01 | 0.02 | — | — | — | 0.00 | 0.00 | 0.01 |
| Equity / assets | 96.4% | 97.3% | 91.7% | 89.6% | 89.2% | 88.5% | 92.0% | 95.6% | 91.6% | 88.7% | 89.6% | 92.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 30, 2026); data from EODHD.
KTTA financial position
At the end of fiscal 2025 (December 31, 2025), Pasithea Therapeutics had total assets of $60.2 million (up 275.0% from a year earlier), total liabilities of $5.0 million and shareholders' equity of $55.2 million. Its current ratio was 11.35. In the latest quarter (ended June 30, 2026) total assets were $51.7 million and equity $49.8 million.
Related: KTTA income statement, KTTA cash flow statement, KTTA key metrics. See the KTTA stock overview for the latest quote and news.
KTTA balance sheet FAQ
What are Pasithea Therapeutics's total assets?
Pasithea Therapeutics reported total assets of $60.2 million at the end of fiscal 2025 (December 31, 2025), compared with $16.1 million a year earlier.
How much cash does Pasithea Therapeutics have?
Pasithea Therapeutics held $55.2 million in cash and short-term investments at the end of fiscal 2025.
What is Pasithea Therapeutics's book value?
Pasithea Therapeutics's shareholders' equity (book value) was $55.2 million at the end of fiscal 2025, or $7.85 per share.
What is Pasithea Therapeutics's current ratio?
Pasithea Therapeutics had current assets of $56.5 million and current liabilities of $5.0 million, a current ratio of 11.35 (it can cover its short-term obligations).
How much goodwill does Pasithea Therapeutics have?
Pasithea Therapeutics carried $3.8 million of goodwill and intangible assets, 6.3% of total assets, at the end of fiscal 2025.